NCT07642492

Brief Summary

The RECapp study is a clinical trial evaluating a digital tool designed to support patients recovering from surgery for oesophageal or stomach cancer. The goal is to reduce symptoms and improve quality of life during recovery. Each year in Sweden, around 1,400 people are diagnosed with these cancers. Although more people are surviving thanks to better treatments, recovery after surgery is often long and challenging, with lasting physical and emotional effects. At the same time, healthcare systems are under pressure to provide long-term support. RECapp is a digital platform developed together with patients and healthcare professionals. It includes a mobile app for patients and a web portal for healthcare staff. Patients can track their symptoms, receive personalised self-care advice, and get guidance on when to contact healthcare. Healthcare providers can follow patients' progress remotely. In this study, 250 patients from across Sweden will take part. They will be randomly assigned to either standard care or standard care plus RECapp. Participants will be followed for six months after surgery, and their symptoms and quality of life will be regularly assessed through questionnaires. If RECapp proves effective, it could become part of future cancer care in Sweden-helping patients feel better supported while also making care more efficient.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
250

participants targeted

Target at P75+ for not_applicable

Timeline
43mo left

Started Jun 2026

Longer than P75 for not_applicable

Geographic Reach
1 country

7 active sites

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 5, 2026

Completed
1 month until next milestone

First Posted

Study publicly available on registry

June 11, 2026

Completed
4 days until next milestone

Study Start

First participant enrolled

June 15, 2026

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 15, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 15, 2029

Last Updated

June 11, 2026

Status Verified

June 1, 2026

Enrollment Period

3.5 years

First QC Date

May 5, 2026

Last Update Submit

June 7, 2026

Conditions

Oesophageal CancerGastric Cancer (Diagnosis)

Keywords

Oesophageal cancerGastric cancerPost surgeryDigital interventionSymptom monitoringSelf-care advice

Outcome Measures

Primary Outcomes (1)

  • Mean modified Memorial Symptom Assessment Scale (MSAS) total score at 13 weeks after hospital discharge

    The modified Memorial Symptom Assessment Scale (MSAS) assesses overall symptom burden. The total score is calculated as the mean of item responses and ranges from 0 to 4, with higher scores indicating greater symptom burden.

    13 weeks after hospital discharge

Secondary Outcomes (9)

  • Mean EORTC QLQ-C30 Summary Score at 26 weeks after hospital discharge

    26 weeks after hospital discharge

  • Mean EORTC QLQ-OG25 overall symptom summary score at 26 weeks after hospital discharge

    26 weeks after hospital discharge

  • Mean modified Memorial Symptom Assessment Scale (MSAS) total score at 26 weeks after hospital discharge

    26 weeks after hospital discharge

  • Mean Memorial Symptom Assessment Scale (MSAS) physical symptom distress score at 26 weeks after hospital discharge

    26 weeks after hospital discharge

  • Mean Memorial Symptom Assessment Scale (MSAS) psychological symptom distress score at 26 weeks after hospital discharge

    26 weeks after hospital discharge

  • +4 more secondary outcomes

Study Arms (2)

Intervention arm

EXPERIMENTAL

Standard care after surgery for oesophageal and gastric cancer + RECapp

Device: The RECapp platform

Control arm

OTHER

Standard care after surgery for oesophageal and gastric cancer for 6 months, thereafter RECapp in addition to standard care for 6 months.

Device: The RECapp platform

Interventions

The RECapp platformDEVICE

The RECapp platform is a device for oesophageal and gastric cancer patients having undergone invasive surgery as part of the curatively intended treatment regime. It is designed to improve recovery and mitigate symptom burden. The RECapp platform includes a mobile application to be used by patients, the RECapp app, and a web application system to be used by healthcare providers, the RECapp care portal. The RECapp app tracks symptom burden through questionnaires, provides feedback on individual status, and provides self-care advice or alerts patients to contact healthcare based on self-reported symptom burden. The RECapp care portal provides healthcare providers with access to the patients' reported history. The RECapp app is to be used by the patient at home, and the RECapp care portal is to be used by healthcare providers in a healthcare setting.

Control armIntervention arm

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who have undergone invasive surgery with curative intent for oesophageal or gastric cancer (including salvage surgery)
  • ≥18 years of age
  • Ability to read, understand, and complete study materials in Swedish, including consent forms, questionnaires, and instructions
  • Access to a smartphone or tablet with personal BankID

You may not qualify if:

  • \- Cognitive impairment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (7)

Sahlgrenska University Hospital

Gothenburg, Sweden

Location

Linköping University Hospital

Linköping, Sweden

Location

Skåne University Hospital

Lund, Sweden

Location

Örebro University Hospital

Örebro, Sweden

Location

Karolinska University Hospital

Stockholm, Sweden

Location

University Hospital of Umeå

Umeå, Sweden

Location

Uppsala University Hospital

Uppsala, Sweden

Location

Related Links

MeSH Terms

Conditions

Esophageal NeoplasmsStomach NeoplasmsDisease

Condition Hierarchy (Ancestors)

Gastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsHead and Neck NeoplasmsDigestive System DiseasesEsophageal DiseasesGastrointestinal DiseasesStomach DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Pernilla Lagergren, Professor

    Surgical care science, Molecular Medicine and Surgery, Karolinska Institute

    STUDY DIRECTOR

Central Study Contacts

Pernilla Lagergren, Professor

CONTACT

+46852482758pernilla.lagergren@ki.se

Marta Lason

CONTACT

+46852485397marta.lason@ki.se

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: A two-arm, unblinded, multisite randomised controlled trial (RCT) with a delayed-start design.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

May 5, 2026

First Posted

June 11, 2026

Study Start

June 15, 2026

Primary Completion (Estimated)

December 15, 2029

Study Completion (Estimated)

December 15, 2029

Last Updated

June 11, 2026

Record last verified: 2026-06

Locations

SE(7)